Accessibility Menu
GSK logo

GSK(OTC) GLAXF

Market Cap$99.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1975)+1,168%
5 Year+26%
1 Year+36%
1 Month-3%
$24.95
-0.28%
-0.07Today
GSK last closing stock price
MetricPriceDate
Last closeUSD 24.952026-07-31
GSK stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-1.43%USD 25.312026-07-24
1 month-3.18%USD 25.772026-07-01
3 month-7.39%USD 26.942026-05-01
Year to date+3.12%USD 24.192025-12-31
1 year+36.15%USD 18.322025-07-31
3 year+53.83%USD 16.222023-07-31
5 year+25.87%USD 19.822021-07-30
Since inception+1,167.89%USD 1.971975-01-06

GSK Financials at a Glance

Market Cap

$99.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

£31.10B

Net Income (TTM)

£4.34B

EPS (TTM)

$1.59

P/E Ratio

15.49

Dividend

$0.90

Beta (Volatility)

-0.13 (Low)

Price

$24.95

Volume

1,291

Open

$24.77

Previous Close

$24.95

Daily Range

$24.77 - $24.95

52-Week Range

$18.10 - $31.48

Estimated Earnings Date

Oct 28, 2026

GLAXF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About GSK

GSK plc is a global healthcare and pharmaceutical leader, headquartered in Brentford, United Kingdom. With a rich history dating back to 1715, GSK operates across various international markets, focusing on the research, development, manufacturing, and commercialization of healthcare products.

Products and Services
  • Pharmaceuticals for respiratory health, HIV, oncology, and more
  • Vaccines for various infectious diseases
  • Consumer healthcare products in wellness, oral health, and nutrition
Growth Outlook
  • Recent quarterly revenue of $7.63 billion indicates strong market demand
  • TTM net income margin of 17.78% reflects effective cost management
  • Strategic partnerships enhance innovation and product pipeline
Financial Highlights
  • TTM revenue of $30.5 billion shows consistent growth trajectory
  • Quarterly EPS of $0.43 demonstrates solid profitability
  • Dividend yield of 3.51% offers attractive returns for investors
GSK plc stands out in the healthcare sector with its diverse product offerings and strategic focus on innovation. The company's recent financial performance highlights its ability to generate substantial revenue and maintain profitability, making it an appealing option for potential investors. The strong dividend yield further enhances its attractiveness, providing a steady income stream alongside capital appreciation potential. With a commitment to advancing healthcare solutions, GSK is well-positioned for future growth in a dynamic market.
AI Generated • Jul 23, 2026

Industry

Pharmaceuticals

Employees

66,841

CEO

Luke Miels, MBA

Headquarters

London, GL WC1A 1DG, GB

GLAXF Financials

Key Financial Metrics (TTM)

Gross Margin

73.29%

Operating Margin

24.12%

Net Income Margin

14.52%

Return on Equity

28.35%

Return on Capital

21.03%

Return on Assets

7.81%

Earnings Yield

6.46%

Dividend Yield

3.59%

Payout Ratio

55.30%

Stock Overview

Market Cap

$99.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.01B

Volume

1.29K

Avg. Volume

793.508

Financials (TTM)

Gross Profit

£22.78B

Operating Income

£7.61B

EBITDA

£9.87B

Operating Cash Flow

£8.04B

Capital Expenditure

-£1.67B

Free Cash Flow

£6.37B

Cash & ST Invst.

£3.08B

Total Debt

£18.11B

GSK Performance Analysis

GSK annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31GBP 36,120,722,0046.3%
20232023-12-31GBP 37,699,276,2674.4%
20242024-12-31GBP 40,092,639,0696.3%
20252025-12-31GBP 43,051,521,1527.4%
GSK sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-10-28-18.6%
Q42025-12-3132.5%
Q12026-03-31-11.5%
Q22026-06-309.4%
GSK annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31GBP 4.51142.5%
20232023-12-31GBP 1.49-67.0%
20242024-12-31GBP 0.79-46.7%
20252025-12-31GBP 1.83130.3%
GSK sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-10-285.7%
Q42025-12-31-56.8%
Q12026-03-31168.8%
Q22026-06-30-76.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

£8.35B

+4.5%

Gross Profit

£6.27B

+7.6%

Gross Margin

75.05%

N/A

Market Cap

$99.97BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.50M

N/A

Employees

66,841

N/A

Net Income

£431.87M

-70.1%

EBITDA

£2.60B

-19.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

£3.08B

-14.8%

Total Debt

£18.11B

-24.0%

Accounts Receivable

£8.02B

+9.5%

Inventory

£6.24B

+2.7%

Long Term Debt

£13.85B

-34.1%

Short Term Debt

£4.26B

+51.4%

Return on Assets

7.81%

N/A

Return on Invested Capital

19.92%

N/A

Free Cash Flow

£2.18B

+49.2%

Operating Cash Flow

£2.51B

+19.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SNYNFSanofi
$83.87+1.17%
CSLLYCSL Limited
$21.64-4.92%
SOAGYSartorius Aktiengesellschaft
$50.35-2.00%
MKGAFMerck KGaA
$168.90-0.13%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$200.75+0.03%
AAPLApple
$308.91-0.07%
AMZNAmazon
$271.58+0.15%
INTCIntel
$90.20-0.01%

Questions About GLAXF

What is the current price of GSK?

GSK is trading at $24.95 per share.

What is the 52-week range for GSK?

Over the past 52 weeks, GSK has traded between $18.10 and $31.48.

How much debt does GSK have?

As of the most recent reporting period, GSK reported total debt of £24.21B.

How much cash does GSK have on hand?

GSK reported £4.12B in cash and cash equivalents in its most recent financial results.

What is GSK’s dividend yield?

GSK currently has a dividend yield of 3.59%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.